Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Finn Gustafsson Added: 1 year ago
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two… View more

Anticoagulation

Heart Failure
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 1 year ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
AHA 25: TUXEDO-2: Ticagrelor vs Prasugrel in Diabetic PCI
Author(s): Sripal Bangalore , Harriette Van Spall Added: 5 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) was joined by the TUXEDO-2 Principal Investigator, Dr Sripal Bangalore to present the findings of this late-breaking randomized trial comparing ticagrelor versus prasugrel in patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)… View more

Anticoagulation

Intervention
Job title: Adjunct Professor of Pharmacology
ESC 25: 4 Heart Failure Trials That Will Change My Practice
Author(s): Michelle Kittleson Added: 7 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial… View more

Anticoagulation

Heart Failure
View from the Thoraxcenter: What's Hot at ACC.25?
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 year ago
Join renowned interventional cardiologists Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) for an exclusive preview of ACC.25's most significant late-breaking science.This episode of View from the Thoraxcenter delivers authoritative analysis of pivotal cardiovascular trials set to revolutionize clinical practice and research. Elevate your conference… View more

Intervention

Heart Failure
Jane Armitage
Research Area(s) / Expertise: Job title: Professor of Clinical Trials and Epidemiology, and Honorary Consultant in Public Health Medicine
Jane Armitage, FRCP, FFPH, OBE, is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine and also Director of Training and Career Development for the Nuffield Department of Population Health. She works on the epidemiology of cardiovascular disease and has led large-scale randomized controlled trials. Dr Armitage is Chief Investigator for the BHF-supported… View more
AHA 25: The OCEAN Trial
Author(s): Atul Verma Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter… View more

Anticoagulation

Electrophysiology & Arrhythmia
Ticagrelor Fails Noninferiority to Prasugrel in TUXEDO-2
Added: 1 month ago Source:  Radcliffe CVRM
Written by Mirjam Boros, Radcliffe CardiologyThe optimal dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in high-risk patients with diabetes and multivessel disease remains a key clinical question. The TUXEDO-2 trial aimed to address this by directly comparing the efficacy and safety of ticagrelor versus prasugrel in this specific patient population… View more

Anticoagulation

Cardiovascular Kidney Metabolic
John McNeill
Job title: Professor and head of School of Public Health and Preventive Medicine
After graduating in medicine from the University of Adelaide Professor McNeil undertook specialist training to become qualified as a consultant in internal medicine and clinical pharmacology. He completed a PhD in Clinical Pharmacology at Melbourne University and was awarded a National Heart Foundation overseas postgraduate research scholarship to study epidemiology at the London School of… View more